Immunotherapy before standard treatment may boost survival in esophageal cancer

This phase 3 trial tests whether adding immunotherapy (sintilimab) and chemotherapy before standard chemoradiotherapy helps people with inoperable esophageal cancer live longer and reduces the chance of the cancer coming back. About 242 adults aged 18-75 with stage 2-4 esophageal cancer will be randomly assigned to receive either the new combination or standard treatment alone. The study tracks survival, side effects, and how well the cancer responds.